Pacylex

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients. First clinical patient dosed at Cross Cancer Institute, Edmonton.

Read More

Recent News

Pacylex

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients

Read More

Pacylex

Pacylex featured as one of "Canada's 10 Most Valuable Healthcare Solution Providers" by Insightscare

Read More

Pacylex

Pacylex Presents Updates on the Journey of PCLX-001 to the Clinic at BIO and FASEB Conferences

Read More
Follow Pacylex